PD-1 inhibitors (nivolumab, labrolizumab, pidilizumab) and PD-L1 inhibitors (BMS-936559, MPDL3280A, MEDI4736) block this immunosuppressive mechanism and increase GBM tumor cell destruction (Razavi et al., 2016). Here, CD274 is linked to glioblastoma.